The company is creating a new flagship manufacturing hub in North Carolina that will enable end-to-end manufacturing of its key medicines in one geographic location.

Backed by the expert team and cutting-edge resources of Re:Build Manufacturing, Ensorcell will offer innovative, high-quality scientific tools designed to accelerate discoveries and improve patient outcomes.

A significant investment from Curewell Capital has been secured by Wilmington PharmaTech, providing growth capital to expand manufacturing and technology capabilities to accelerate drug development with U.S. manufacturing.

The USD 3 billion facility will expand the company’s capacity to produce oral medicines, enabling it to meet rising customer demand, and will also strengthen its global supply chain.

The CDMO has completed the expansion of its Pessano facility in Milan, Italy, adding increased packaging and warehousing capacity that has already been authorized by the AIFA and is producing validation and commercial batches.

Located in Stein, Switzerland, the new GMP licensed line will enable the company to provide integrated, end-to-end solutions for the whole biologics and bioconjugation value chain.

Through the strategic acquisition of a facility from WuXi Biologics based in Germany, Terumo has strengthened its ability to serve both domestic and international pharmaceutical companies.

Located in Hopewell, N.J., the new facility signifies the first major manufacturing investment for Enzene within the U.S., strengthening the company’s commitment to supporting innovation and supply chain resilience in the country.

This latest funding will bolster the additional investment and private capital and will allow Delpharm to modernize its Boucherville facility to be able to meet the growing demand for injectable drugs.

The strategic investments by the CRDMO, which are aligned with its long-term strategy, will strengthen its integrated oligonucleotide platform and capabilities to delivery ADC solutions.

The location of the facility has been purposefully chosen to be as central as possible to cell and gene therapy companies located across the U.S. and will allow the company to meet growing demand for pDNA development and manufacturing services.

Through this acquisition, ESTEVE will expand its contract development and manufacturing services for small-molecule APIs from pre-clinical through to commercial manufacturing within the U.S.

Marking a strategic move for the company, the expansion will enable acceleration of pre-clinical development of the circVec circular RNA expression data platform.

An official groundbreaking ceremony marked the start of construction on the service provider’s new site in Des Plaines, Ill., which will house a clinical production facility for aseptic manufacturing, new process areas for material preparation and compounding, in addition to other buildings.

To meet growing demand for advanced, domestic biomanufacturing capabilities, Enzene Biosciences is scaling up its soon-to-launch New Jersey facility to 80,000 square feet and integrating its proprietary continuous manufacturing platform.

Located within Bend’s Oregon facility, the four new process development and manufacturing suites will support spray drying and unit operations, helping the company to meet the growing needs of clients in these areas.

The company has added the further sterile fill/finish capacity to the site in response to continued growth in demand for its drug product services.

The new facility adds to the company’s existing infrastructure and is set to provide comprehensive technical support for bioprocessing to biopharmaceutical companies and contract manufacturers.

This latest investment into expanding its manufacturing capabilities reinforces the company’s commitment to the U.S. and enhances its global biomanufacturing network.

The acquisition will provide PCI with a large-scale manufacturing hub on the West Coast of the U.S., complementing its existing global facilities.